Searching News Database: DURECT
HSMN NewsFeed - 17 Jan 2020
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
DURECT Corporation Announces Outcome of FDA Advisory Committee Meeting for POSIMIR(R)
HSMN NewsFeed - 27 Jun 2019
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
DURECT Announces Submission to FDA of a Full Response to the POSIMIR(R) Complete Response Letter
HSMN NewsFeed - 20 Sep 2017
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development
HSMN NewsFeed - 14 Oct 2009
AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development
AcelRx Pharmaceuticals Hires Nigel Ray as Vice President of Business Development
HSMN NewsFeed - 27 Feb 2009
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
HSMN NewsFeed - 10 Jun 2008
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
HSMN NewsFeed - 7 Apr 2008
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
Endo Pharmaceuticals Provides Updates on FROVA(R) and CHRONOGESIC(R) Clinical Development Programs
HSMN NewsFeed - 27 Jun 2007
DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
DURECT Announces the Initiation of Sufentanil Patch Phase II Study by Endo Pharmaceuticals
HSMN NewsFeed - 17 May 2007
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
HSMN NewsFeed - 4 Apr 2007
Threshold Pharmaceuticals Appoints David R. Hoffmann to Board of Directors
Threshold Pharmaceuticals Appoints David R. Hoffmann to Board of Directors
HSMN NewsFeed - 5 May 2006
ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-Based Oxycodone) Commences Pivotal Phase III Program
ORADUR(TM) Technology Milestone: Remoxy(TM) (ORADUR-Based Oxycodone) Commences Pivotal Phase III Program
Additional items found! 40
Members Archive contains
40 additional stories matching:
DURECT
(Password required)
DURECT
(Password required)